Expression of programmed death ligand 1 (PD-L1) in urothelial bladder carcinoma (immunohistochemical and histopathological study)

Document Type : Original Article

Authors

1 Pathology department, Faculty of medicine, Beni- Suef University, Beni-Suef, 62514, Egypt

2 Urology department, Faculty of medicine, Beni- Suef University, Beni-Suef, 62514, Egypt

3 Pathology department, Faculty of medicine, Cairo University, Cairo, 11865, Egypt

Abstract

The aim of this work is to evaluate the immunohistochemical expression of PD-L1 in tumor cells of urothelial bladder carcinoma. PD-L1 immunoexpression was assessed on 20 cases of radical cystectomy specimens using monoclonal rabbit anti- PD-L1 antibody.  Extent of membranous PD-L1 expression was assigned in each case. Tumor cells showing > 5% expression were considered positive. PD-L1was seen in 6 (30%) cases [1 case score +2 and 5 cases score +3], while 14(70%) cases were negative [7 cases score 0 and 7 cases score +1]. PD-L1 expression in tumor cells was insignificantly correlated with different available clinicopathological parameters such as sex, pathological stage, associatedbilharzial infestation, necrosis, perineural invasion and associated tumor infiltrating mononuclear cells (TIMCs), although PD-L1 positivity tend to predominate in advanced pathological stage of tumor (T3 and T4). These findings may have clinical implications for the management of patients with PD-L1 positive urothelial bladder carcinoma.

Keywords

Main Subjects

References

  1. Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F. (2017). Bladder cancer incidence and mortality: a global overview and recent trends. European urology, 71(1), 96-108.
  2. Ferlay J, Shin H R, Bray F et al., (2008): Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer.
  3. Helal, T., Salman, M., & Ezz-Elarab, S. (2015). Pathology-based cancer registry 2001-2010. Chapter, 4, 17-25.
  4. ElMoneim, H. M. A., Tawfik, H. M., El Sherbiny, Y. M., & Tawfiek, E. R. (2011). Analysia of Her2/neu overexpression and amplification in urothelial carcinoma of the bladder associated with Cox-2 overexpression. Int J Cancer Res, 7(1), 8-24.
  5. Johansson, H., Andersson, R., Bauden, M., Hammes, S., Holdenrieder, S., & Ansari, D. (2016). Immune checkpoint therapy for pancreatic cancer. World journal of gastroenterology, 22(43), 9457.
  6. Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015). Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology, 33(17), 1974.
  7. Bidnur, S., Savdie, R., & Black, P. (2016). Inhibiting immune checkpoints for the treatment of bladder cancer. Bladder Cancer, 2(1), 15-25.
  8. Carosella, E. D., Ploussard, G., LeMaoult, J., & Desgrandchamps, F. (2015). A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. European urology, 68(2), 267-279.
  9. Zou, W., & Chen, L. (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 8(6), 467-477.‏
  10. Purdie, C., Quinlan, P., Jordan, L., Ashfield, A., Ogston, S., Dewar, J., & Thompson, A. (2014). Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. British journal of cancer, 110(3), 565.
  11. Boorjian, S. A., Sheinin, Y., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M. & Frank, I. (2008). T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clinical Cancer Research, 14(15), 4800-4808.
  12. Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S. & Gettinger, S. N. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 515(7528), 563.
  13. Moch, H., Humphrey, P., Ulbright, T., & Reuter, V. (2016b). Tumours of the urinary tract. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th ed. Lyon, France: IARC.
  14. Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K. & Winchester, D. P. (2017). The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA: a cancer journal for clinicians, 67(2), 93-99.‏
  15. Bellmunt, J., Mullane, S., Werner, L., Fay, A., Callea, M., Leow, J. & Freeman, G. (2015). Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Annals of Oncology, 26(4), 812-817.
  16. Faraj, S. F., Munari, E., Guner, G., Taube, J., Anders, R., Hicks, J. & Drake, C. (2015). Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology, 85(3), 703. e701-703. e706.
  17. Mukamel E, Shohat B, Servadio C. Immunological profile of patients with transitional cell carcinoma of the bladder. Br J Urol. 1982;54:11–15
  18. Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I. & Kwon, E. D. (2007). PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata: associations with localized stage progression. Cancer: Interdisciplinary International Journal of the American Cancer Society, 109(8), 1499-1505.
  19. Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007). Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunology, Immunotherapy, 56(8), 1173-1182.
  20. Thompson, R. H., Dong, H., & Kwon, E. D. (2007). Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clinical Cancer Research, 13(2), 709s-715s

Files

Share

How to cite

Statistics